FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads
FDA's early intervention regarding misleading advertisements for King's morphine product Embeda gave the company a head start on reviewing its promotional pieces, but it did not mean the company could escape from the official warning letter
You may also be interested in...
Agency says it is seeing confusion in the marketplace when it comes to distinguishing between agency-approved labeling claims and advertising about products that are intended to be abuse deterrent.
Lilly promised to remove offending images from promotional materials for its imaging product, but the agency followed up with a “notice of violation” letter two months later anyway.
A claim for tamper-resistance rather than broad abuse-deterrence appears to be the immediate path forward for companies seeking to differentiate a new opioid product by its ability to impede recreational use.